Christophe Arbet-Engels - 31 Aug 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Medical Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
31 Aug 2023
Net transactions value
+$1,600,000
Form type
4
Filing time
05 Sep 2023, 16:15:36 UTC
Previous filing
16 Aug 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Option (right to buy) Award $1,600,000 +1,250,000 $1.28 1,250,000 31 Aug 2023 Common Stock 1,250,000 $1.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.